The efficacy of oral ribavirin in the treatment of Crimean-Congo hemorrhagic fever in Iran
The efficacy of oral ribavirin in the treatment of Crimean-Congo hemorrhagic fever in Iran
复制标题
DOI：
10.1086/375058
复制
发表时间：
2003-06-15
影响因子：
11.8
通讯作者：
Zeinali, M
中科院分区：
文献类型：
--
作者：
Mardani, M;Jahromi, MK;Zeinali, M
我们比较了疑似克里米亚-刚果出血热（CCHF）患者接受口服利巴韦林治疗和未接受治疗的死亡率。139例疑似CCHF治疗患者中有97例（69.8%）存活，69例确诊CCHF治疗患者中有61例（88.9%）存活。口服利巴韦林的疗效在确诊的CCHF患者中为80%，在疑似CCHF患者中为34%。考虑到观察性研究的局限性，我们得出结论，口服利巴韦林是一种有效的治疗出血型慢性充血性心力衰竭。
We compared the mortality rate among patients suspected of having Crimean-Congo hemorrhagic fever (CCHF) who received treatment with oral ribavirin and those who did not. Ninety-seven (69.8%) of 139 treated patients suspected of having CCHF survived, and 61 (88.9%) of 69 treated patients with confirmed CCHF survived. The efficacy of oral ribavirin was 80% among patients with confirmed CCHF and 34% among patients suspected of having CCHF. Considering the limitations of observational studies, we conclude that oral ribavirin is an effective treatment for the hemorrhagic form of CCHF.